Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:47 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 9,940 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Clear all
Completed Not applicable Interventional

A Study of 1592U89 in HIV-Infected Adults

NCT00002200
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 4:47 AM EST
Completed No phase listed Observational

Targeting Effective Analgesia in Clinics for HIV - Patient Cohort

NCT02525731
View directory record Official record
Conditions
HIV Infection, Pain, Drug Dependence
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Nov 3, 2026, 4:47 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

NCT00428337
View directory record Official record
Conditions
HIV Infections
Interventions
EP-1233, MVA-mBN32
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
San Francisco, California • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Nov 3, 2026, 4:47 AM EST
Active, not recruiting No phase listed Observational

Anal High-risk HPV, HSIL, and Microbiome Among Hispanic Peoples Living With HIV (PLWH)

NCT06651957
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, High-Grade Squamous Intraepithelial Lesions
Interventions
Biospecimen Collection, Questionnaires
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 3, 2026, 4:47 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.

NCT05867212
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Injection [Apretude]
Drug
Lead sponsor
Kelley-Ross & Associates, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Nov 3, 2026, 4:47 AM EST
Withdrawn Phase 1 Interventional

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

NCT05079451
View directory record Official record
Conditions
HIV Infections
Interventions
3BNC117-LS, 10-1074-LS
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Nov 3, 2026, 4:47 AM EST
Completed Not applicable Interventional

A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus

NCT00002095
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
19
States / cities
Berkeley, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 4:47 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults

NCT00239577
View directory record Official record
Conditions
Dengue
Interventions
Live attenuated tetravalent dengue vaccine, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Nov 3, 2026, 4:47 AM EST
Completed Phase 3 Interventional Results available

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

NCT04502030
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
Interventions
Panzyga, Placebo
Biological · Other
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
15
States / cities
St. Petersburg, Florida • Columbus, Georgia • Macon, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 4:47 AM EST
Completed Phase 2 Interventional

A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci

NCT01519492
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Wound Infection, Cutaneous Abscess, Burn Infection, Cellulitis
Interventions
AFN-12520000
Drug
Lead sponsor
Affinium Pharmaceuticals, Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Buena Park, California • Chula Vista, California • La Mesa, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Nov 3, 2026, 4:47 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

NCT00845429
View directory record Official record
Conditions
Influenza, Orthomyxoviruses, Myxovirus Infection
Interventions
Influenza virus vaccine - cell-based (2007-2008 Formulation), Influenza virus vaccine (2007-2008 Formulation)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
15
States / cities
Hoover, Alabama • Mobile, Alabama • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Nov 3, 2026, 4:47 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV

NCT05828095
View directory record Official record
Conditions
HIV-1-infection
Interventions
INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Nov 3, 2026, 4:47 AM EST
Not yet recruiting Early Phase 1 Interventional

Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease

NCT06799039
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Interventions
Xylitol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Nov 3, 2026, 4:47 AM EST
Active, not recruiting No phase listed Observational

Host Response to Infection and Treatment in Filarial Diseases

NCT00001230
View directory record Official record
Conditions
Filariasis, Helminthiasis, Parasitic Infection, Mansonelliasis, Onchocerciasis
Interventions
Diethylcarbamazine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 3, 2026, 4:47 AM EST
Completed Not applicable Interventional Results available

Intervention to Retain HIV-positive Patients in Medical Care

NCT01537367
View directory record Official record
Conditions
Primary Care Appointment Keeping
Interventions
Enhanced contact plus behavioral skills, Enhanced contact only, Standard of Care
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Nov 3, 2026, 4:47 AM EST
Completed Phase 1 Interventional

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

NCT00352300
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions
Adjuvant Therapy, Carboplatin, Paclitaxel, Pegfilgrastim
Procedure · Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
11
States / cities
Orange, California • Iowa City, Iowa • Camden, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Nov 3, 2026, 4:47 AM EST
Completed Phase 2 Interventional Results available

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

NCT00018031
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Peginterferon alfa-2b, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Nov 3, 2026, 4:47 AM EST
Completed No phase listed Observational

Long-Term Data Collection From Participants in Adult AIDS Clinical Trials

NCT00001137
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older
Enrollment
5,982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
75
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Nov 3, 2026, 4:47 AM EST
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Japanese Bridging Study Conducted in the United States

NCT00947245
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
BMS-791325, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
20 Years to 49 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Nov 3, 2026, 4:47 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Study of Oral Papillomavirus In Teens and Twenties

NCT00994019
View directory record Official record
Conditions
STD
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 26 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Nov 3, 2026, 4:47 AM EST
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

NCT01731691
View directory record Official record
Conditions
HIV Disease
Interventions
α1 Proteinase Inhibitor, Placebos
Biological · Drug
Lead sponsor
Institute for Human Genetics and Biochemistry
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Nov 3, 2026, 4:47 AM EST
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

NCT00509691
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique
Biological · Genetic · Other
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Nov 3, 2026, 4:47 AM EST
Terminated No phase listed Observational

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

NCT00709397
View directory record Official record
Conditions
HIV-1 Infection
Interventions
blood drawing
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2010 · Synced Nov 3, 2026, 4:47 AM EST
Completed Phase 2 Interventional Results available

The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

NCT04312997
View directory record Official record
Conditions
COVID-19
Interventions
PUL-042 Inhalation Solution, Placebo
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Orange, California • San Bernardino, California • Coral Gables, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Nov 3, 2026, 4:47 AM EST